Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 4/20 | 0.46 |
| ▸ | TOP1 | P11387 | 2/20 | 0.45 |
| ▸ | CYCS | P99999 | 2/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL174717 | 0.98 | TERT (0.47) | TERTTOP1CYCSENPP2 | |
| SCHEMBL1315059 | 0.96 | TERT (0.46) | TERTTOP1CYCSENPP2 | |
| SCHEMBL30894449 | 0.96 | TERT (0.46) | TERTTOP1CYCSENPP2 | |
| SCHEMBL31460436 | 0.96 | TERT (0.46) | TERTTOP1CYCSENPP2 | |
| SCHEMBL1313450 | 0.96 | TERT (0.46) | TERTTOP1CYCSENPP2 | |
| SCHEMBL4020034 | 0.96 | TERT (0.46) | TERTTOP1CYCSENPP2 | |
| SCHEMBL3940635 | 0.96 | TERT (0.46) | TERTTOP1CYCSENPP2 | |
| SCHEMBL1954413 | 0.96 | TERT (0.46) | TERTTOP1CYCSENPP2 | |
| Hydrochloric Acid SCHEMBL6865971 | 0.94 | TOP1 (0.45) | TERTTOP1CYCSENPP2 | |
| Hydrochloric Acid SCHEMBL21493256 | 0.94 | TOP1 (0.45) | TERTTOP1CYCSENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110423185-B | Method for selectively oxidizing cumene compound | 浙江工业大学 | 2022-03-18 | — | — | CN | claimed |
| EP-1104427-B1 | PROCESS FOR THE PREPARATION OF N-(PHOSPHONOMETHYL)GLYCINE BY OXIDIZING N-SUBSTITUTED N-(PHOSPHONOMETHYL)GLYCINE | MONSANTO TECHNOLOGY LLC (US) | 2005-03-09 | — | — | EP | claimed |
| US-20040143134-A1 | Process for the preparation of N-(phosphonomethyl)glycine by oxidizing N-substituted N-(phosphonomethyl)glycine | MONSANTO TECHNOLOGY LLC | 2004-07-22 | — | — | US | claimed |
| US-20100167918-A1 | ALIGNED CARBON NANOTUBE WITH ELECTRO-CATALYTIC ACTIVITY FOR OXYGEN REDUCTION REACTION | THE UNIVERSITY OF CHICAGO (US) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040143134-A1 | Process for the preparation of N-(phosphonomethyl)glycine by oxidizing N-substituted N-(phosphonomethyl)glycine | GNMT, GRHPR, GLRA3 | TERT 3877/4885TOP1 3845/4885CYCS 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.